Abstract
The clinical trial of 10% urea cream (FERZEA®) was performed using a total of 18 patients with xerotic dermatoses: keratodermia tylodes parmaris progressiva (KTPP)(9 cases); xerosis (5); ichthyosis (2); eczema rhagadiforme (1); eczema squamosum (1).
Out of the patients investigated, 13 showed excellent improvement, one good, two moderate, and no improvement in 2 cases.
No side effects were observed in all the patients.
It was concluded from this study that FERZEA® has excellent properties in both efficacy and safety and is a useful preparation for treatment of xerotic dermatoses which are associated with decreased water holding capacity of the skin.
